NCT06399315
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
Eilean Therapeutics·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- AML
- Drug/Device/Intervention
- ZE46-0134 or placebo
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Eilean Therapeutics
- Location
- Perth, Australia
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jul 28, 2023
- End date
- Nov 01, 2024
- Enrollment
- 64 participants
Primary outcome
Plasma concentration
Summary
This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of
 ZE46-0134 efficacy in Healthy Volunteers after single and multiple daily doses of the study
 drug
ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06399315
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06399315 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eilean Therapeutics and is currently Recruiting. The study focuses on AML. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.